They have established dosing schedules, and their safety profiles and side effects have been monitored, unlike GLP-1 patches
In vitro human plasma stability Human plasma was preheated at 37 C for 15 min before being spiked with a final concentration of 0.25 mM of the peptide or conjugate
Our bodies are dependent on glucagon to help keep our blood glucose in normal ranges, however, if you have too much glucagon in your circulation, your cells wont store sugar
The Risks Another challenge with GLP-1 use in someone with type 1 diabetes is the potential risk of hypoglycemia, or low blood sugar
[DOI] [PubMed] [Google Scholar] 38.Hesp AC, et al
As a result, the needles and drug content within the polymer matrix dissolve and remain in the body, while the backing layer can be removed after a few minutes, once the needles have been inserted into the skin and come into contact with body fluids